Browsing Tag
Public Offering
12 posts
Can Elong Power’s $7.6M fundraise offset dilution risks with faster execution in battery systems?
Elong Power’s $7.6M offering uses complex warrant triggers that reshape equity dynamics. Find out how this impacts investor sentiment and capital strategy.
Pasithea Therapeutics raises $60m in discounted public offering as biotech funding momentum returns
Find out how Pasithea Therapeutics’ $60 million stock offering reshapes its clinical runway, dilution outlook, and investor sentiment.
Why Inhibikase Therapeutics (NASDAQ: IKT) is tapping public markets now for $100m in new funding
Find out how Inhibikase Therapeutics plans to use its $100M equity raise to fund pipeline trials and what it means for shareholders in 2025.
Salarius Pharmaceuticals raises $7m in underwritten offering to fund merger and R&D pipeline
Find out how Salarius Pharmaceuticals is raising $7 million through a structured equity offering as it funds a merger and next-generation biotech pipeline.
BioHarvest Sciences completes nearly $20m financing round — what it means for shareholders and future growth
Find out how BioHarvest Sciences’ $19.9 million public offering is shaping its expansion plans, investor sentiment, and biotech growth outlook today.
Precision BioSciences $75m stock and warrant offering sparks debate over biotech funding momentum
Precision BioSciences completes a $75 million stock and warrant offering to fund its ARCUS gene-editing pipeline — find out how this move reflects broader biotech funding trends.
Shipping firm Rubico launches $7.5m offering, sparking sharp stock decline and dilution fears
Rubico Inc.’s $7.5 million underwritten offering sparked a sharp stock sell-off and raised concerns about dilution and strategy. Find out what it means for investors.
Savara’s $130m stock offering strengthens cash position ahead of MOLBREEVI launch
Savara raises $130 million through stock and warrant sale to fund MOLBREEVI’s rare-disease launch—find out how this deal reshapes its commercialization path.
Ontrak Health announces $4m public stock offering with warrant package to bolster working capital
Ontrak Health (NASDAQ: OTRK) prices $4 million public offering to fund working capital amid AI-driven behavioral health expansion. Institutional investors eye warrant vote.
Bone Biologics prices $5m equity and warrant offering to accelerate spinal fusion trial development
Bone Biologics Corporation has priced a $5 million public offering to advance its spine fusion therapy trials and intellectual property. Learn what this means for investors.